(MedPage Today) — SAN FRANCISCO — Incorporating the recently approved bispecific antibody zanidatamab (Ziihera) into first-line treatment for HER2-positive gastroesophageal cancer topped trastuzumab plus chemotherapy, a phase III trial showed…
Source link : https://www.medpagetoday.com/meetingcoverage/mgics/119319
Author :
Publish date : 2026-01-07 20:16:00
Copyright for syndicated content belongs to the linked Source.
